Blood Clinical Collection focus on Lymphoid Malignancies

Program aimed at specialists in Hematology

A course of ten teaching numbers that contains scientific reviews in e-learning format. You will have the latest news in the care of patients with hematological problems, both in the study of Chronic Lymphocytic Leukemia, and in the management of patients in their clinical practice.

This program is sponsored by AstraZeneca and has the scientific endorsement of the SEHH (Spanish Society of Hematology and Hemotherapy).

By completing the course you will be able to obtain credits from the Spanish National Health System (09/036991-MD).

Sign up!

Calendar

Dates: 27-03-2024 / 26-03-2025
Credits have been requested from the Spanish National Health System
Nº: 09/036991-MD
Class hours: 20h

Lesson 1: Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial (2h)
27 march 2024

Lesson 2: Richter syndrome: novel insights into the biology of transformation (2h)
27 march 2024

Lesson 3: Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut (2h)
24 april 2024

Lesson 4: High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations (2h)
29 may 2024

Lesson 5: Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor (2h)
26 june 2024

Lesson 6: PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma (2h)
31 july 2024

Lesson 7: Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells (2h)
28 august 2024

Lesson 8: Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities (2h)
25 september 2024

Lesson 9: Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL (2h)
30 october 2024

Lesson 10: Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis (2h)
27 november 2024

Collaborators

Dr. Javier de la Serna

Head of the Hematology Service.

Hospital Universitario 12 de Octubre, Madrid.

Dra. Lucrecia Yáñez San Segundo

Hematology Department. Marqués de Valdecilla Research Institute (IDIVAL), Santander, Cantabria. Coordinator of Hematopoietic Transplantation and Cell Therapy (II).

Hospital Universitario Marqués de Valdecilla, Santander, Cantabria.